DC-SIGN is a dendritic cell-specific C-type lectin receptor that recognizes highly glycosylated ligands expressed on the surface of various pathogens. This receptor plays an important role in the early stages of many viral infections, including HIV, which makes it an interesting therapeutic target. Glycomimetic compounds are good drug candidates for DC-SIGN inhibition due to their high solubility, resistance to glycosidases and non-toxicity. We studied the structural properties of the interaction of the tetrameric DC-SIGN extracellular domain (ECD), with two glycomimetic antagonists, a pseudo-mannobioside (1) and a linear pseudo-mannotrioside (2). Though the inhibitory potency of 2, as measured by SPR competition experiments, was one order of magnitude higher than that of 1, crystal structures of the complexes within DC-SIGN carbohydrate recognition domain showed the same binding mode for both compounds. Moreover, when coupled to multivalent scaffolds, the inhibitory potencies of these compounds became uniform. Combining isothermal titration microcalorimetry, analytical ultracentrifugation and dynamic light scattering techniques to study DC-SIGN ECD interaction with these glycomimetics, revealed that 2 is able, without any multivalent presentation, to cluster DC-SIGN tetramers leading to an artificially overestimated inhibitory potency. The use of multivalent scaffolds presenting 1 or 2 in HIV trans-infection inhibition assay confirms the loss of potency of 2 upon coupling and the equal efficacy of chemically simpler compound 1. This study documents a unique case where, among two active compounds chemically derived, the compound with the lower apparent activity is the optimal lead for further drug development.
Introduction
Immature dendritic cells (DCs) are professional antigen presenting cells of the innate immunity.
They routinely survey peripheral tissues for invading pathogens, and present the antigens to the T cells thus boosting pathogen-specific adaptive immune responses (1) . Pattern recognition receptors (PRRs) of DCs are instrumental in capturing pathogens through the recognition of pathogen associated molecular patterns (PAMPs). DCs express a wide range of PRRs including toll-like receptors (TLRs) and C-type lectin receptors (CLRs), enabling DCs to recognize the majority of invading pathogens (2, 3) . One of these PRRs is DC-SIGN (Dendritic Cell-Specific ICAM-3 Grabbing Non-integrin), a CLR abundantly expressed on immature DCs that has been extensively studied because of its intriguing roles in immunity (4, 5) . DC-SIGN was recognized as a receptor hijacked by various dangerous pathogens, including viruses like HIV and Ebola, bacteria, fungi and parasites, to evade or modulate host immune responses enhancing their infectivity (6, 7) . These findings highlighted DC-SIGN as an interesting therapeutic target and inspired many research groups to attempt the design of antagonists for infection prevention.
DC-SIGN is a type II membrane protein with a cytosolic domain followed by a transmembrane region and an extracellular domain (ECD). The latter is organized into an elongated neck region and a globular C-terminal carbohydrate recognition domain (CRD), which binds fucose and mannosecontaining oligosaccharides in a calcium-dependent manner (8, 9) . The neck drives lectin's oligomerization into tetramers and serves as a stalk raising CRDs well above the cell membrane (320 Å) and presenting them in a tetravalent manner with ~40 Å distances between vicinal binding sites (10) . These tetramers are further clustered to microdomains at the cell membrane (11, 12) .
Although monosaccharide affinity to DC-SIGN is very low, multimeric DC-SIGN organization together with clustered presentation of pathogen glycans leads to the affinity enhancement through avidity effects. Hence, the strategies to develop good DC-SIGN inhibitors not only involve optimization of the monovalent ligands, but also include extensive search for the proper scaffolds for multimeric ligand presentation, thus ensuring efficient competition with highly multivalent PAMPs (reviewed in (13, 14) ).
Our groups focus on the development of fucose-and mannose-based glycomimetic inhibitors of DC-SIGN. We recently published series of LewisX trisaccharide mimics, which had slightly better affinity as compared to natural LewisX and an improved selectivity to DC-SIGN versus langerin (15) , a C-type lectin implicated in the protection from HIV infection (16) . We have also developed two mannose-type glycomimetics, corresponding to a terminal branch of high-mannose glycan, which are the target ligands for DC-SIGN on the gp120 HIV envelope protein. Thus, we produced a Manα1-2Man mimic pseudomannobioside (1) and a Manα1-2Manα1-6Man mimic pseudomannotrioside (2) and evaluated them as DC-SIGN inhibitors. The initial surface plasmon resonance (SPR) competition assay indicated that 2 had an order of magnitude lower IC 50 than 1 (17) . Hence, this compound was selected to generate a tetravalent dendron 3.2, which in turn was tested for the ability to inhibit HIV trans-infection of T-lymphocytes mediated by B-THP-1/DC-SIGN cells (17) as well as HIV transmission inhibition in cervical tissue explants (18) . Indeed, the dendron 3.2 displayed a very promising anti-HIV activity in these assays and was demonstrated to be non-toxic.
Additionally, the third generation (G3) Boltorn type dendrimers 4 bearing an average of 30-32 copies of 1 (compound 4.1) or 2 (compound 4.2) were built and evaluated in SPR competition experiments and DC-SIGN-mediated Ebola infection assays (19) . Both dendrimers were highly active in inhibiting Ebola infection, but surprisingly, no significant difference was found in their potencies (IC 50 ~20 nM for both compounds). The SPR competition experiments gave a similar outcome ( Figure   1 ): while the activities of the monovalent compounds have almost one order of magnitude difference in favor of 2, nearly the same affinities were observed for tetravalent (3.1 and 3.2) and multivalent (4.1 and 4.2) forms of 1 and 2. Furthermore, the monovalent and tetravalent forms of 2 (2 and 3.2) had basically the same activities. Recently, we have structurally characterized the binding of 1 to DC-SIGN CRD (20) . X-ray crystallography of co-crystallized DC-SIGN CRD/1 complex revealed an unexpected binding mode of the molecule, which was confirmed by solution studies using transfer NOE (tr-NOESY) and saturation transfer difference (STD) NMR experiments. Although 1 and its natural counterpart Manα1-2Man have similar affinities for DC-SIGN as observed in SPR competition test (IC 50 values 1.0 mM and 0.9 mM, respectively), our results indicated that 1, contrary to Manα1-2Man, has only a single binding mode within DC-SIGN CRD, a prerequisite for a good lead compound for further chemical modifications to improve affinity and selectivity. We also found that 1 has an enhanced selectivity towards DC-SIGN compared to langerin. This is an important feature for the development of microbicides that shouldn't interfere with the protective function of langerin, especially due to its expression on Langerhans cells, which constitute the very first barrier for invading HIV virions in genital and rectal mucosa (16) .
Herein we present our efforts to unravel the underlying reasons for the above-described surprising behavior of the compound 2. Through series of biophysical studies we found that this small glycomimetic, to our surprise, acts as a bivalent molecule, and this peculiar property led to an artificial 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 overestimation of its potency in competition assays where soluble DC-SIGN tetramers are used. This work emphasizes the importance of thorough and critical structural investigation of leads from primary screening campaigns and highlights specific design challenges for the discovery of potent antagonists of lectins' activity.
Results and discussion
The study described in this paper was motivated by the need to understand why the relatively high efficiency of 2 is lost when the compound is tethered on multivalent scaffolds, an essential information in order to shape our ligand design program. We have co-crystallized the latter glycomimetic with DC-SIGN CRD and solved the X-ray structure. Furthermore, we investigated the Similarly to the recently published structure of DC-SIGN/1, the crystals of 2 in complex with DC-SIGN CRD also had a single copy of CRD in an asymmetric unit with P4 3 2 1 2 space group. The structure was solved by molecular replacement, at 1.35 Å resolution (see Table S1 in SI). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 than those described previously for 1,pdb 2xr5) with the protein were observed. While the nonreducing mannose moiety made coordination bonds with Ca 2+ ion with its 3-OH and 4-OH groups and C6 methylene of the cyclohexane ring retained the van der Waals contact with Val351 side chain of the protein, the reducing-end mannose was oriented away from the protein and apparently didn't make any contacts. Moreover, the electron densities of this second mannose unit as well as of its ethylazide linker were rather poorly defined, suggesting a higher flexibility of these parts ( Figure 2A ). Thus the revealed structure of 2 within DC-SIGN didn't provide any clue about the reason why it could be a better ligand than 1 for DC-SIGN having apparently the same binding mode and contacts with the protein. This intriguing finding prompted us to investigate the interaction further on.
Thermodynamic characterization of DC-SIGN interaction with 1 and 2
To evaluate whether positive entropy contributions were responsible for the higher affinity of monovalent 2 relative to 1, we analyzed the interaction of both glycomimetics with tetrameric DC-SIGN by ITC. At the first set, the same experimental conditions with identical concentrations of interaction components were used. The pseudosaccharides (12.7 mM) were titrated into lectin solution (71 µM with respect to binding sites). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 respectively, but the low affinity prevented reliable interaction enthalpies and entropies to be obtained and compared (21) . Nevertheless, an intriguing outcome could be observed: the first injections of 2 to DC-SIGN solution resulted in twice more heat released using the same concentrations of both ligands and the receptor. This suggested a higher affinity of 2 than 1, which could not be explained by the Xray data since 2 didn't seem to make any other additional contacts compared to 1.
Because 2 had apparently higher affinity to DC-SIGN, we repeated the titration with different concentrations (1.18 mM of 2 titrated to 214 µM of DC-SIGN ECD) in order to perform it in a more relevant concentration range ( Figure 3C highlights even a stronger difference in the activities of the two molecules.
Furthermore, fitting of the data in Figure 3C yielded n=0.5 stoichiometry. Because additional DC-SIGN ECD purification step has been applied for this experiment (SI Figure S2) , the contribution of non-active binding sites to n<1 value was excluded. Interaction with n=0.5 in this case means that two DC-SIGN CRDs share one molecule 2, or in other words, two DC-SIGN tetramers bind four copies of 2, on average. Since 2 is a relatively small molecule, it is impossible for it to reach two different CRDs within the same tetramer (the approximate distance between vicinal binding sites within the tetramer is 40 Å(10)). Hence, this stoichiometry suggests that the same molecule of 2 bridges two DC-SIGN tetramers by simultaneously binding to one CRD in each, and would explain why under the same experimental conditions titrating DC-SIGN with 2 released markedly more heat than titrating with 1.
Analytical Ultracentrifugation analysis of DC-SIGN/1 and DC-SIGN/2 complexes
To check the hypothesis that 2 can bridge DC-SIGN tetramers, sedimentation velocity (SV) experiments were performed on the samples retrieved from the ITC measurements, where the ligands were in 26-fold excess relative to the lectin binding sites. Figure 4 compares the sedimentation profiles registered at 42000 rpm at the same time intervals (1 h) for each of the three samples (pure protein, Figure 4A ; DC-SIGN+1, Figure 4B ; DC-SIGN+2, Figure 4C ). Clearly, DC-SIGN alone or incubated with 1 sediments similarly, while DC-SIGN incubated with 2 moves faster, suggesting that the association of DC-SIGN tetramers is induced by 2 but not by 1. The data were treated in terms of size distribution analysis. Figure 4D 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 To elucidate the origin of these larger species, a second set of SV experiments was performed using several 2/DC-SIGN molar ratios (0, 0.25, 0.5, 1, 5, 11 and 27) and the results are summarized in Figure 5 . These variations of the absolute s 20w -values are likely not related to experimental errors, but reflect the complexity of a reaction boundary: for fast reactions, indeed, association-dissociation processes affect the sedimentation boundary (23, 24) . The integration of each c(s) curve under the two peaks gives, on one hand, the total absorbance reflecting DC-SIGN ECD concentration (similar at all ratios), and on the other hand, the weight-average sedimentation coefficient value (s w ) that does not depend on the interaction kinetics. We attempted the s w -isotherm analysis using SEDPHAT, but fitting heteroassociation models failed, most likely due to the presence of a more complicated system and to nonideality conditions. Nevertheless, the data analysis in terms of s w -value ( Figure 5B ) clearly shows that (23, 24) , the studied system is apparently too complicated (tetravalent protein, presumably bivalent ligand, excluded volume effects), therefore no model could be fitted to the data.
Characterization of DC-SIGN/2 interaction by static and dynamic light scattering

DC-SIGN association, induced by 2, was also examined by Static (SLS) and Dynamic Light
Scattering (DLS) simultaneously using the same sample conditions as for the second AUC study.
Correlation curves and hydrodynamic radius (R H ) distributions from DLS show the presence of one contribution for most of the samples (example in Figure S3 ). Larger species (R H ≈100 nm) were marginally detected in negligible amounts of the peak intensity and are considered as irrelevant dust. 
2/DC-SIGN ECD ratio, MW increases from 148 kDa for DC-SIGN ECD alone and reaches a constant
value of 350 kDa at ratio 5. Correspondingly, R H increases from 7.5 nm without 2 to a maximum value of 10.4 nm at ratio 11, followed by a slight and perhaps irrelevant decrease to 10.2 nm at ratio 27. The evolution of MW and R H reflects the general behavior observed in AUC ( Figure 5B ). We note that in Altogether, AUC, DLS and SLS data support that 2 promotes the dimerization of DC-SIGN tetramers when 2/DC-SIGN ECD ratios are between 1 and 5, while higher excess of 2 saturates all the binding sites, which interrupts the further bridging.
In order to get an insight to the possible organization of compound 2-mediated DC-SIGN assembly, we generated a model of a supramolecular complex where two DC-SIGN ECDs were bridged by four compounds 2 using a symmetry docking algorithm (25) . The best resulting model apparently showed no steric clashes between both facing DC-SIGN ECD ( Figure 7) . Finally, the constructed model was subjected to HydroPro calculations (26) , and yielded the theoretical s value for the model structure of 6.8 S, which in turn gives R H value of 9.6 nm. This R H value is in agreement, within standard deviation, with the experimentally measured R H maximum ( Figure 6 ). This suggests that the supra-molecular assembly is compatible with such an elongated conformation. However, this model must be taken only as a rough approximation of the real situation: it must be kept in mind that such a system is presumably rather dynamic due to relatively low affinity of single mannose residue, and thus possibly adopts different conformations and/or a mix of species in solution totally loaded with 2 ( Figure 7 ) or partially bridged by one, two or three molecules of compound 2. 
Comparison of the ability of multivalent systems bearing 1 or 2 to inhibit HIV trans-infection
In our previous study, due to the better activity of 2 observed in SPR competition assays, only this molecule was used to generate a tetravalent dendron which was tested with good results in cellular studies of HIV trans-infection inhibition (17) . Upon full characterization of the binding modes of 1 and 2 and after the results described in this paper, inhibition of HIV-1 trans-infection was readdressed in the same cellular model using both 1 and 2-based tetravalent dendrons (3.1 and 3.2) in order to compare their HIV blocking abilities. Additionally, 32-valent dendrimers bearing 1 or 2 ( Figure 1A) were also studied. The results showed that both dendrons were able to reduce HIV transmission to CD4 + T-cells by a very similar extent ( Figure 8 ): 5 µM concentrations displayed ~50% infection inhibition, while incubation with 50 µM dendrons reduced infection almost to 90%.
Due to the higher binding avidity, the dendrimers with both 1 and 2 displayed significantly higher efficiencies than dendrons and almost completely inhibited the infection at 50 µM concentration. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 59 60 Despite slight differences of inhibitory efficiencies of 1 and 2 bearing dendrimers at lower concentrations, these data correlate well with above described results and confirm once again that both pseudosaccharides have very similar activities once they are tethered to multivalent scaffolds. It definitely confirms that 1 is comparable to 2 and any residual difference is easily offset by the superior synthetic accessibility of 1, which lends itself to easier optimization.
In summary, the development of multivalent glycomimetic antagonists required to efficiently compete with natural multivalent interactions (27) 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 biological relevance (28, 29) , the case presented here is unique, considering the small size of the molecule and the low affinity of single mannose residues for DC-SIGN. Probably, the absence of steric hindrance between both DC-SIGN ECDs in the complex, as suggested by the modeling, allows such bridging to occur. In biological systems the most common situation of multivalent sugar/protein interactions is the formation of carbohydrate-lectin lattices (30) and lectin bridging property of glycomimetic molecules has been previously engineered in relatively large multimeric presentations (31) (32) (33) (34) . However, to the best of our knowledge, bridging effects by an oligosaccharide as small as a (pseudo)trimer have never been observed with one exception in the particular case of crystallization conditions (33) .
Unfortunately, this property of 2 depends on a precise format of the interaction assay and 
Methods
Compound synthesis. 
DC-SIGN production and purification
DC-SIGN CRD-StrepTagII (S-CRD) and ECD constructs were produced as described previously (10, 20) .
DC-SIGN/2 co-crystallization, data collection and structure solution
Crystallization 
Static and Dynamic Light Scattering
The SLS and DLS were performed using DynaPro/Nanostar instrument (Wyatt Technology Corp., Santa Barbara, USA) equipped with 658 nm laser at 90° scattering angle. 
Analytical Ultracentrifugation
SV experiments were performed using Beckman XL-I analytical ultracentrifuge with AN-50 TI rotor (Beckman instruments), at 20°C and 42 000 rpm, using 55 µl samples, loaded into the two-channel 0.15 cm path-length centerpieces with sapphire windows (Nanolytics). The absorbance at 280 nm was monitored every 5 or 11 min for the first and second set experiments, respectively, with a 30 µm radial step size.
The samples were prepared in buffer-A. The first set of experiments was done with samples retrieved from first set ITC measurements, thus contained DC-SIGN ECD alone at 62 µM, or with 1.63 mM 1 or
2.
The identical freshly prepared samples were used for the control, giving identical results. For the regularization, a 0.68 confidence level was used. All s-values were corrected for solvent density and viscosity, and thus are given as s 20w -values.
DC-SIGN/2 bridging complex modeling.
To generate a tetrahedral DC-SIGN assembly, we used a novel symmetry docking algorithm (25) . We assembled a tetrahedral octamer possessing D4 symmetry starting from a monomer of the reported crystal structure (PDB 2xr6) with a single mannose in the Ca 2+ binding-site using the exhaustive search in six degrees of freedom. Then, we selected an octameric solution that fulfilled geometric constraints at the coiled-coil start and fitted the pseudotrisaccharide 2 into its binding pocket using Autodock/Vina 
Infection studies.
The studies of HIV trans-infection inhibition by 3.1, 3.2, 4.1 and 4.2 without removal of compounds prior to virus exposure were performed as described previously (17) . 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 
